Strategy

Syntaxin’s strategy is to demonstrate the high value of our platform through realising the potential to deliver a rich seam of medicines with large market opportunities. The full exploitation of the platform will then represent a great source of future medicines for an acquiring company and will offer current investors a profitable exit.

The platform affords great opportunity for developing specific product-based partnerships. Alignment with other companies that can bring a synergy to the TSI platform (for example, protein scaffold companies) will enhance the breadth of cell-specific targeting to broaden product opportunities. The early pipeline will be built in this way through partnership.

Syntaxin’s management is mindful of the long-term potential of the platform to build a sustainable business, and our actions and approach to drug development reflect our experience of delivering new platform drugs to the market. Additional funds will be utilised to extend the platform portfolio in a balanced way to demonstrate the possibilities for development of a range of successful medicines.